Voyager Therapeutics (NASDAQ:VYGR) CFO Sells $17,598.36 in Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) CFO Nathan Jorgensen sold 4,668 shares of the business’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $3.77, for a total transaction of $17,598.36. Following the completion of the sale, the chief financial officer directly owned 151,416 shares of the company’s stock, valued at approximately $570,838.32. The trade was a 2.99% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Voyager Therapeutics Stock Performance

Shares of VYGR stock traded up $0.04 on Thursday, reaching $4.13. 151,278 shares of the company were exchanged, compared to its average volume of 584,842. The company has a market cap of $229.63 million, a price-to-earnings ratio of -1.91 and a beta of 1.30. Voyager Therapeutics, Inc. has a 1 year low of $2.64 and a 1 year high of $5.55. The business has a 50-day moving average price of $3.86 and a 200 day moving average price of $4.11.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Wedbush reissued an “outperform” rating and issued a $8.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, November 11th. HC Wainwright dropped their price objective on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, November 12th. Finally, Wall Street Zen downgraded shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $13.75.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Ethic Inc. acquired a new position in Voyager Therapeutics during the second quarter worth approximately $123,000. Los Angeles Capital Management LLC purchased a new position in shares of Voyager Therapeutics during the second quarter worth about $50,000. Sphera Funds Management LTD. raised its stake in Voyager Therapeutics by 70.1% during the 4th quarter. Sphera Funds Management LTD. now owns 339,761 shares of the company’s stock valued at $1,335,000 after acquiring an additional 140,000 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in Voyager Therapeutics during the 4th quarter worth approximately $120,000. Finally, Opaleye Management Inc. purchased a new position in shares of Voyager Therapeutics in the 4th quarter valued at approximately $4,704,000. 48.03% of the stock is owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.